Literature DB >> 26398596

Sulfonylurea Receptor 1 in Humans with Post-Traumatic Brain Contusions.

Tamara Martínez-Valverde1, Marian Vidal-Jorge1, Elena Martínez-Saez2, Lidia Castro1, Fuat Arikan1,3, Esteban Cordero3, Andreea Rădoi1, Maria-Antonia Poca1,3, J Marc Simard4, Juan Sahuquillo1,3.   

Abstract

Post-traumatic brain contusions (PTBCs) are traditionally considered primary injuries and can increase in size, generate perilesional edema, cause mass effect, induce neurological deterioration, and cause death. Most patients experience a progressive increase in pericontusional edema, and nearly half, an increase in the hemorrhagic component itself. The underlying molecular pathophysiology of contusion-induced brain edema and hemorrhagic progression remains poorly understood. The aim of this study was to investigate sulfonylurea 1/transient receptor potential melastatin 4 (SUR1-TRPM4) ion channel SUR1 expression in various cell types (neurons, astrocytes, endothelial cells, microglia, macrophages, and neutrophils) of human brain contusions and whether SUR1 up-regulation was related to time postinjury. Double immunolabeling of SUR1 and cell-type- specific proteins was performed in 26 specimens from traumatic brain injury patients whose lesions were surgically evacuated. Three samples from limited brain resections performed for accessing extra-axial skull-base tumors or intraventricular lesions were controls. We found SUR1 was significantly overexpresed in all cell types and was especially prominent in neurons and endothelial cells (ECs). The temporal pattern depended on cell type: 1) In neurons, SUR1 increased within 48 h of injury and stabilized thereafter; 2) in ECs, there was no trend; 3) in glial cells and microglia/macrophages, a moderate increase was observed over time; and 4) in neutrophils, it decreased with time. Our results suggest that up-regulation of SUR1 in humans point to this channel as one of the important molecular players in the pathophysiology of PTBCs. Our findings reveal opportunities to act therapeutically on the mechanisms of growth of traumatic contusions and therefore reduce the number of patients with neurological deterioration and poor neurological outcomes.

Entities:  

Keywords:  brain contusion; brain edema; human; immunofluorescence; sulfonyurea receptor 1

Mesh:

Substances:

Year:  2015        PMID: 26398596      PMCID: PMC4589328          DOI: 10.1089/neu.2014.3706

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  49 in total

1.  Morphology of cortical contusions.

Authors:  E FREYTAG; R LINDENBERG
Journal:  AMA Arch Pathol       Date:  1957-01

Review 2.  The sulfonylurea receptor.

Authors:  S J Ashcroft; F M Ashcroft
Journal:  Biochim Biophys Acta       Date:  1992-12-15

3.  Pathogenesis of the mass effect of cerebral contusions: rapid increase in osmolality within the contusion necrosis.

Authors:  Y Katayama; T Mori; T Maeda; T Kawamata
Journal:  Acta Neurochir Suppl       Date:  1998

Review 4.  Hemorrhagic progression of a contusion after traumatic brain injury: a review.

Authors:  David Kurland; Caron Hong; Bizhan Aarabi; Volodymyr Gerzanich; J Marc Simard
Journal:  J Neurotrauma       Date:  2011-12-05       Impact factor: 5.269

5.  Glibenclamide reduces secondary brain damage after experimental traumatic brain injury.

Authors:  K Zweckberger; K Hackenberg; C S Jung; D N Hertle; K L Kiening; A W Unterberg; O W Sakowitz
Journal:  Neuroscience       Date:  2014-04-30       Impact factor: 3.590

6.  Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury.

Authors:  Ashish D Patel; Volodymyr Gerzanich; Zhihua Geng; J Marc Simard
Journal:  J Neuropathol Exp Neurol       Date:  2010-12       Impact factor: 3.685

7.  Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after traumatic brain injury with biochemical markers of BBB leakage and inflammatory response.

Authors:  D Vajtr; O Benada; J Kukacka; R Průša; L Houstava; P Ťoupalík; R Kizek
Journal:  Physiol Res       Date:  2008-04-01       Impact factor: 1.881

Review 8.  Cerebral endothelial damage after severe head injury.

Authors:  Hiroyuki Yokota
Journal:  J Nippon Med Sch       Date:  2007-10       Impact factor: 0.920

Review 9.  Sulfonylurea receptor 1 in central nervous system injury: a focused review.

Authors:  J Marc Simard; S Kyoon Woo; Gary T Schwartzbauer; Volodymyr Gerzanich
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-20       Impact factor: 6.200

10.  The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel.

Authors:  Seung Kyoon Woo; Min Seong Kwon; Alexander Ivanov; Volodymyr Gerzanich; J Marc Simard
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

View more
  20 in total

1.  Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury.

Authors:  Ruchira M Jha; Ava M Puccio; Sherry Hsiang-Yi Chou; Chung-Chou H Chang; Jessica S Wallisch; Bradley J Molyneaux; Benjamin E Zusman; Lori A Shutter; Samuel M Poloyac; Keri L Janesko-Feldman; David O Okonkwo; Patrick M Kochanek
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

2.  Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury.

Authors:  Ruchira Menka Jha; Theresa A Koleck; Ava M Puccio; David O Okonkwo; Seo-Young Park; Benjamin E Zusman; Robert S B Clark; Lori A Shutter; Jessica S Wallisch; Philip E Empey; Patrick M Kochanek; Yvette P Conley
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-19       Impact factor: 10.154

Review 3.  Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications.

Authors:  Fanuel T Hagos; Solomon M Adams; Samuel M Poloyac; Patrick M Kochanek; Christopher M Horvat; Robert S B Clark; Philip E Empey
Journal:  Exp Neurol       Date:  2019-02-21       Impact factor: 5.330

4.  Transient Receptor Potential Melastatin 4 Induces Astrocyte Swelling But Not Death after Diffuse Traumatic Brain Injury.

Authors:  Karen M Gorse; Mary Kate Lantzy; Eun D Lee; Audrey D Lafrenaye
Journal:  J Neurotrauma       Date:  2018-06-05       Impact factor: 5.269

5.  Downstream TRPM4 Polymorphisms Are Associated with Intracranial Hypertension and Statistically Interact with ABCC8 Polymorphisms in a Prospective Cohort of Severe Traumatic Brain Injury.

Authors:  Ruchira M Jha; Shashvat M Desai; Benjamin E Zusman; Theresa A Koleck; Ava M Puccio; David O Okonkwo; Seo-Young Park; Lori A Shutter; Patrick M Kochanek; Yvette P Conley
Journal:  J Neurotrauma       Date:  2019-02-01       Impact factor: 5.269

Review 6.  Genetic underpinnings of cerebral edema in acute brain injury: an opportunity for pathway discovery.

Authors:  Elayna Kirsch; Natalia Szejko; Guido J Falcone
Journal:  Neurosci Lett       Date:  2020-05-26       Impact factor: 3.046

7.  ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI.

Authors:  Ruchira M Jha; Ava M Puccio; David O Okonkwo; Benjamin E Zusman; Seo-Young Park; Jessica Wallisch; Philip E Empey; Lori A Shutter; Robert S B Clark; Patrick M Kochanek; Yvette P Conley
Journal:  Neurocrit Care       Date:  2017-04       Impact factor: 3.210

Review 8.  Pathophysiology and treatment of cerebral edema in traumatic brain injury.

Authors:  Ruchira M Jha; Patrick M Kochanek; J Marc Simard
Journal:  Neuropharmacology       Date:  2018-08-04       Impact factor: 5.250

Review 9.  The pharmacogenomics of severe traumatic brain injury.

Authors:  Solomon M Adams; Yvette P Conley; Amy K Wagner; Ruchira M Jha; Robert Sb Clark; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey
Journal:  Pharmacogenomics       Date:  2017-10-04       Impact factor: 2.533

Review 10.  BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema.

Authors:  Melissa Pergakis; Neeraj Badjatia; Seemant Chaturvedi; Carolyn A Cronin; W Taylor Kimberly; Kevin N Sheth; J Marc Simard
Journal:  Expert Opin Investig Drugs       Date:  2019-10-24       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.